These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 8017869

  • 1. The interferon-beta 1b clinical trial and its implications for other trials.
    Paty DW.
    Ann Neurol; 1994; 36 Suppl():S113-4. PubMed ID: 8017869
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Interferon beta-1b for the treatment of multiple sclerosis.
    Petri T, Weber-Diehl F.
    J Biotechnol; 1995 Nov 21; 43(1):74-5. PubMed ID: 8573325
    [No Abstract] [Full Text] [Related]

  • 4. Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure.
    Stone LA, Frank JA, Albert PS, Bash CN, Calabresi PA, Maloni H, McFarland HF.
    Neurology; 1997 Sep 21; 49(3):862-9. PubMed ID: 9305355
    [Abstract] [Full Text] [Related]

  • 5. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).
    Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, Montanari E, Zaffaroni M, Independent Comparison of Interferon (INCOMIN) Trial Study Group.
    Lancet; 2002 Apr 27; 359(9316):1453-60. PubMed ID: 11988242
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Role of interferons in demyelinating diseases.
    Arnason BG, Toscas A, Dayal A, Qu Z, Noronha A.
    J Neural Transm Suppl; 1997 Apr 27; 49():117-23. PubMed ID: 9266421
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. New tools for biotech product development.
    Quay S.
    Biotechnology (N Y); 1995 Apr 27; 13(4):319-20. PubMed ID: 9678946
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab.
    Barbero P, Bergui M, Versino E, Ricci A, Zhong JJ, Ferrero B, Clerico M, Pipieri A, Verdun E, Giordano L, Durelli L, INCOMIN Trial Study Group.
    Mult Scler; 2006 Feb 27; 12(1):72-6. PubMed ID: 16459722
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Multiple sclerosis: what have we learned from magnetic resonance imaging studies?
    Khoury SJ, Weiner HL.
    Arch Intern Med; 1998 Mar 23; 158(6):565-73. PubMed ID: 9521220
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The quality-of-life effects of interferon beta-1b in multiple sclerosis. An extended Q-TWiST analysis.
    Schwartz CE, Coulthard-Morris L, Cole B, Vollmer T.
    Arch Neurol; 1997 Dec 23; 54(12):1475-80. PubMed ID: 9400356
    [Abstract] [Full Text] [Related]

  • 18. Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis.
    Goodin DS, Traboulsee A, Knappertz V, Reder AT, Li D, Langdon D, Wolf C, Beckmann K, Konieczny A, Ebers GC, 16-Year Long Term Follow-up Study Investigators.
    J Neurol Neurosurg Psychiatry; 2012 Mar 23; 83(3):282-7. PubMed ID: 22193561
    [Abstract] [Full Text] [Related]

  • 19. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b.
    Rice GP, Paszner B, Oger J, Lesaux J, Paty D, Ebers G.
    Neurology; 1999 Apr 12; 52(6):1277-9. PubMed ID: 10214759
    [Abstract] [Full Text] [Related]

  • 20. Use of interferon beta 1b for multiple sclerosis. Importance of relapses must not be underestimated.
    Cardy P.
    BMJ; 1996 Nov 16; 313(7067):1263. PubMed ID: 8939142
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.